Trial
NCT03420521
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Bristol-Myers Squibb
Condition
Neuroendocrine Tumors
Intervention
Nivolumab
Why stopped
Loss of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-09